SOURCE: Industrial Biotechnology Corporation

November 14, 2006 15:41 ET

Industrial Biotechnology Corporation's Vice President of Business Development and Scientific Operations to Speak at BioFlorida 2006

SARASOTA, FL -- (MARKET WIRE) -- November 14, 2006 -- Industrial Biotechnology Corporation (PINKSHEETS: IBTY) (IBC), a company dedicated to new biotechnologies and innovations in the chemical industry, today announced that Gary Howell, IBC's VP Business Development and Scientific Operations, will share some of his insights on industrial biotech industry development and progress at IBC with colleagues in Florida in a presentation at the 9th Annual BioFlorida meeting this week.

Dr. Howell, who joined IBC in January 2006, has extensive experience in business development, commercialization of biological and chemical research, technology development and management across a range of industries. Dr. Howell has overseen and led diverse businesses within consumer products, biotechnology, R&D, technology transfer, and financial services. He has held leadership roles in organizations ranging from start-ups to Fortune 500 corporations with responsibilities in technology assessment, strategy development, market research and business development.

Prior to joining IBTY, Dr. Howell served as Director of the Cincinnati Center for Clinical Research and Head of Venture Development at Cincinnati Children's Hospital Medical Center; interim CEO of Genomatix (now Intrexon), a biotechnology company; and while at Procter & Gamble served as Manager of Ph.D./M.D. Recruiting and various Analytical Chemistry and Technology/Product Development departments.

"Florida has a dynamic and rapidly growing base of biotechnology research and industries that provides as a critical foundation for growing young companies like IBC," said Andy Badolato, CEO of IBTY. "We are pleased to be a part of this year's Conference and look forward to benefiting from connections with the many excellent biotechnology business leaders and researchers through the opportunities afforded by this excellent program." Dr. Howell adds, "BioFlorida 2006 offers an exciting opportunity to exchange ideas and perspectives with colleagues in Florida across the broad scope of bioscience interests and capabilities. We are looking forward to introducing our Company and the third wave of Biotechnology innovation to our colleagues and neighbors in Florida, while exploring new possibilities for collaboration, synergy and mutual value creation."

About BioFlorida and the 9th Annual State-wide Conference

BioFlorida 2006 includes internationally renowned speakers, presenters and panelists that will explore the convergence and synergies between the key life-science sectors (biotech, pharmaceuticals, medical devices, diagnostics and ag-bio), as well as other topics of critical importance to both researchers and industry executives in all aspects of the life science field. The program for the 9th Annual Conference includes thought-provoking panel discussions, thought-leading keynote speakers and special cross-industry networking opportunities. Session tracks focus on bio-science, emerging-business topics, mature-business topics, and include concurrent sessions with the bi-annual Florida Marine Biotechnology Summit V.

BioFlorida is the statewide industry organization representing life science industry in Florida, one of the fastest growing bio hubs in the world. BioFlorida focuses on creating and maintaining a favorable business and legislative environment, advancing the commercialization of research and working with investors, private enterprise, government, academia and the financial and service sectors to further develop existing companies, launch start-up companies and attract new business to Florida.

This year's theme for BioFlorida 2006, "Intersections: Converging Fields, Emerging Opportunities," provides an excellent opportunity for partnerships and productive interactions between entrepreneurs, entities and investors as development of commercial actions, enterprise cooperation.

About Industrial Biotechnology Corporation

Industrial Biotechnology Corporation (IBC) enables the biological production of chemicals through a combination of licensed patents, intellectual property and proprietary systems. We accomplish this through our ALCHEMx Productions Platforms™ which are a systematic, streamlined approach to biologically manufacture chemicals more efficiently, at significantly lower costs, and with substantially lower environmental impact than traditional methods. IBC and its partners plan to produce and market new and established biologically produced chemicals to the pharmaceutical, bio-energy, agricultural, biopesticides, fine chemicals, flavors and fragrances, cosmeceuticals, biomaterials and biopolymer industries. For more information about Industrial Biotechnology Corporation, please visit its website at

Forward-Looking Statements

Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words such as "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe Industrial Biotechnology Corporation's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Industrial Biotechnology Corporation, as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Industrial Biotechnology Corporation believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Industrial Biotechnology Corporation does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact Information

  • Contact:
    Public & Investor Relations
    Industrial Biotechnology Corporation
    2033 Main Street
    Sarasota, FL 34237
    Email Contact